Tempus AI

Tempus AI, Inc., formerly known as Tempus Labs, is an American health-technology company headquartered in Chicago, Illinois. Founded in 2015 by entrepreneur Eric Lefkofsky, the company was created soon after Lefkofsky's wife was diagnosed with breast cancer. That experience helped shape Tempus's focus on using large-scale medical and molecular datasets to support more individualized treatment decisions. The company's core business combines genome sequencing, clinical data analysis, laboratory testing, and artificial-intelligence software. Its work is centered on precision medicine: the use of a patient's molecular profile and clinical history to help clinicians understand disease, identify potentially relevant therapies, and make more informed treatment decisions. Oncology has been Tempus's primary clinical area, particularly through genetic testing and other diagnostic services for cancer patients. The company has also expanded its stated activities into cardiology, radiology, and pharmacogenomic testing related to depression. Tempus's business model spans both laboratory and software capabilities. It processes biological and medical information, generates or aggregates structured datasets, and develops computational tools intended for use by healthcare providers, researchers, and other healthcare organizations. This combination positions the company between a diagnostic laboratory, a clinical-data company, and an artificial-intelligence healthcare platform. Its offerings are designed to connect test results and other patient information with clinical decision-making rather than treating genomic sequencing as an isolated laboratory service. The company has pursued partnerships and acquisitions to extend its data and testing capabilities. In June 2024, Tempus and SoftBank Group announced a healthcare artificial-intelligence joint venture in Japan called SB Tempus. The venture was intended to analyze medical data with AI and develop personalized treatment recommendations. In November 2024, Tempus agreed to acquire Ambry Genetics, a California-based genetic-testing company, in a transaction described as having a value of $600 million in cash and stock. The proposed acquisition would broaden Tempus's genetic-testing portfolio. Tempus became a publicly traded company on the Nasdaq on June 14, 2024, using the ticker symbol TEM. Its disclosed investors have included SoftBank Group, Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, and Google. The company's advisory board has included Jennifer Doudna and Scott Gottlieb. Reference material states that Tempus employed approximately 3,800 people at the end of 2025. A further proposed expansion came in July 2026, when Tempus agreed to acquire cancer-testing company Personalis in a transaction valued at approximately $1.5 billion; the deal was expected to close in late 2026 or early 2027 according to the cited reference material.

Tempus AI was established in Chicago in 2015 by Eric Lefkofsky. The company emerged from a personal motivation connected with Lefkofsky's wife's breast-cancer diagnosis and was organized around the idea that medical decisions could be improved through the systematic use of genomic and clinical information. Rather than limiting its activities to conventional laboratory testing, Tempus developed a broader model that combined sequencing, diagnostics, data infrastructure, and artificial intelligence. Oncology became the company's principal area of activity. Tempus performs genomic sequencing and provides precision-medicine services intended to help characterize cancer and inform treatment planning. Its approach relies on combining molecular test results with other clinical information so that healthcare professionals can evaluate a patient's disease in a more individualized context. The company subsequently described applications in additional clinical areas, including cardiology and radiology, as well as pharmacogenomic testing for patients with depression. Tempus's development reflects the convergence of three sectors: clinical diagnostics, biomedical data management, and AI-assisted healthcare. Its laboratory work produces molecular information, while its software and analytical systems are intended to make that information useful to clinicians, researchers, and healthcare organizations. This positioning has allowed the company to present itself as both a precision-medicine provider and a healthcare AI business. The company expanded its strategic reach through partnerships and acquisitions. In June 2024, it partnered with SoftBank Group to create SB Tempus, a Japanese healthcare AI joint venture. The stated purpose of the venture was to analyze medical data and develop personalized treatment recommendations. In the same period, Tempus reached the public markets, listing on the Nasdaq on June 14, 2024, under the symbol TEM. Investors identified in reference material include SoftBank Group, Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, and Google. In November 2024, Tempus agreed to acquire Ambry Genetics, a California-based genetic-testing company, for a reported $600 million in cash and stock. The transaction was intended to strengthen Tempus's testing capabilities and extend its genetic-services portfolio. Reference material also identifies Jennifer Doudna and Scott Gottlieb as members of the company's advisory board and reports approximately 3,800 employees at the end of 2025. In July 2026, Tempus agreed to acquire Personalis in a transaction valued at approximately $1.5 billion. The proposed transaction would add Personalis's NeXT Personal cancer test to Tempus's oncology portfolio and was expected to close in late 2026 or early 2027. The available material does not establish whether that transaction ultimately closed. Tempus's continuing identity is that of a healthcare company seeking to use genomic and clinical data, supported by AI, to make precision medicine more broadly actionable.

• 2026

  Agreement to acquire Personalis

  [1]Tempus AIen.wikipedia.org

  Tempus agreed to acquire Personalis in a transaction valued at approximately $1.5 billion, subject to completion under the reported timetable.

• 2024

  Tempus lists on the Nasdaq

  [1]Tempus AIen.wikipedia.org

  Tempus became a public company on June 14, 2024, trading under the ticker symbol TEM.

• 2024

  SB Tempus is formed in Japan

  [1]Tempus AIen.wikipedia.org

  Tempus and SoftBank Group established a Japanese healthcare AI joint venture intended to use medical data to develop personalized treatment recommendations.

• 2024

  Agreement to acquire Ambry Genetics

  [1]Tempus AIen.wikipedia.org

  Tempus agreed to acquire Ambry Genetics in a cash-and-stock transaction valued at $600 million.

• 2015

  Tempus is founded in Chicago

  [1]Tempus AIen.wikipedia.org

  Eric Lefkofsky founded Tempus, initially known as Tempus Labs, as a health-technology company focused on genomic data, clinical information, and precision medicine.

A data-intensive precision-medicine and healthcare artificial-intelligence company combining genomic testing, clinical information, and computational tools to support individualized care.

• Molecular diagnostics

  Oncology genomic testing

  Tempus's central product area is genomic testing for cancer patients. The company sequences patient samples and uses molecular information alongside clinical data to support precision-medicine decisions. These services are intended to help characterize tumors and provide clinicians with information relevant to treatment planning.

• Healthcare artificial intelligence

  Precision-medicine data and AI services

  Tempus develops computational systems that organize and analyze genomic and clinical information. Its AI-oriented services are positioned as tools for healthcare professionals and organizations seeking to interpret complex medical datasets and support more individualized clinical decisions.

• Clinical data and diagnostics

  Cardiology services

  Beyond oncology, Tempus identifies cardiology as an area in which it applies data and artificial intelligence. The available reference material does not specify individual cardiology product names or launch dates.

• Medical imaging and AI

  Radiology services

  Tempus also applies its health-data and AI capabilities to radiology. The available material describes the clinical area but does not provide enough information to identify a distinct branded product or detailed commercial specifications.

• Pharmacogenomics

  Pharmacogenomic testing for depression

  The company provides pharmacogenomic testing associated with depression care. Such testing is presented as part of Tempus's broader effort to connect patient biology with treatment decisions, although the supplied reference does not specify a separate product name.

• Cancer testing

  NeXT Personal

  NeXT Personal is a cancer test associated with Personalis. Tempus's proposed acquisition of Personalis would add the test to its oncology portfolio, but the supplied material does not establish that the transaction has closed.

• 2026

  Acquire PersonalisM&A

  Background

  Tempus sought to strengthen its oncology testing portfolio by adding Personalis and its NeXT Personal cancer test.

  Action taken

  Tempus agreed to acquire Personalis in a transaction valued at approximately $1.5 billion.

  Aftermath

  The deal was expected to close in late 2026 or early 2027 according to the supplied reference, but the available material does not confirm completion.

  Transaction value. Approximately $1.5 billion (July 2026 announcement)

  Source

• 2024

  Acquire Ambry GeneticsM&A

  Background

  Tempus sought to expand its genetic-testing capabilities through the purchase of Ambry Genetics, a California-based genetic-testing company.

  Action taken

  Tempus agreed to a cash-and-stock acquisition reportedly valued at $600 million.

  Aftermath

  The supplied reference material does not provide sufficient information to confirm the closing date or subsequent integration results.

  Transaction value. $600 million (November 2024 announcement)

  Source

• 2024

  Create SB Tempus with SoftBankStrategy

  Background

  Tempus pursued international expansion of its healthcare AI model and sought to apply its data and analytical capabilities in Japan.

  Action taken

  Tempus and SoftBank Group formed SB Tempus, a Japanese joint venture focused on analyzing medical data and developing personalized treatment recommendations.

  Aftermath

  The supplied reference material does not provide detailed operating results or product-launch information for the joint venture.

  Source

• 2026.11.02

  Reported2026.11.02

  Tempus AI reports third-quarter 2026 results[2]Tempus AI公布2026年第三季度业绩rttnews.com

  Tempus AI reported third-quarter 2026 financial results, including revenue of $411.54 million, up 23% year over year, and a net loss of $14.85 million.

• 2026.11.02

  Reported2026.11.02

  Tempus raises FY2026 revenue guidance[2]Tempus AI公布2026年第三季度业绩rttnews.com

  Tempus raised its full-year 2026 revenue guidance to $1.60 billion–$1.605 billion, representing approximately 25% growth compared with 2025 revenue.

Read more

1. 1Tempus AIen.wikipedia.org
2. 2Tempus AI公布2026年第三季度业绩rttnews.com